Clinical progress note: Xylazine use and its sequelae

Haley Allcroft^{1

2}, Erica Heiman³, Jenna L Butner^{2

3}

Affiliations

¹ Yale Physician Associate Program, New Haven, Connecticut, USA.
² Yale School of Public Health, New Haven, Connecticut, USA.
³ Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

Haley Allcroft et al. J Hosp Med. 2024 Aug.

. 2024 Aug;19(8):713-715.

doi: 10.1002/jhm.13338. Epub 2024 Apr 1.

Haley Allcroft^{1

2}, Erica Heiman³, Jenna L Butner^{2

3}

¹ Yale Physician Associate Program, New Haven, Connecticut, USA.
² Yale School of Public Health, New Haven, Connecticut, USA.
³ Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

No abstract available

References

1. Wong SC, Curtis JA, Wingert WE. Concurrent detection of heroin, fentanyl, and xylazine in seven drug‐related deaths reported from the Philadelphia Medical Examiner's Office. J Forensic Sci. 2008;53(2):495‐498. doi:10.1111/j.1556-4029.2007.00648.x
1. The White House. Biden‐Harris administration designates fentanyl combined with xylazine as an emerging threat to the United States. 2023. Accessed April 17, 2023. https://www.whitehouse.gov/ondcp/briefing-room/2023/04/12/biden-harris-a...
1. Friedman J, Montero F, Bourgois P, et al. Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend. 2022;233:109380. doi:10.1016/j.drugalcdep.2022.109380
1. Johnson J, Pizzicato L, Johnson C, Viner K. Increasing presence of xylazine in heroin and/or fentanyl deaths, Philadelphia, Pennsylvania, 2010‐2019. Inj Prev. 2021;27(4):395‐398. doi:10.1136/injuryprev-2020-043968
1. Kariisa M, O'Donnell J, Kumar S, Mattson CL, Goldberger BA. Illicitly manufactured fentanyl–involved overdose deaths with detected xylazine—United States, January 2019–June 2022. MMWR Morb Mortal Wkly Rep. 2023;72:721‐727. doi:10.15585/mmwr.mm7226a4